Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept + Pembrolizumab + Chemotherapy in Advanced HNSCC
NCT04675333Phase 2Active, not recruiting
- Sponsor
- ALX Oncology
- Start
- May 2021
- Primary completion
- Mar 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of evorpacept in head and neck squamous cell carcinoma (HNSCC), sponsored by ALX Oncology. Started May 2021; status: active, not recruiting.
02
Drugs
evorpacept
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04675333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675333.